Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Verteporfin

Known as: BPD verteporfin, Verteporfinum, BPD-MA 
A synthetic light-activated agent with photodynamic activity. Upon systemic administration, verteporfin accumulates in neovessels in the eye and… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
PURPOSE To assess the effects of verteporfin photodynamic therapy (PDT) combined with ranibizumab or alone versus ranibizumab… Expand
Is this relevant?
Highly Cited
2012
Highly Cited
2012
The Drosophila TEAD ortholog Scalloped is required for Yki-mediated overgrowth but is largely dispensable for normal tissue… Expand
  • figure 1
Is this relevant?
Highly Cited
2010
Highly Cited
2010
A semiconductor package includes a lower package including a lower package substrate, a lower semiconductor chip disposed on the… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
OBJECTIVE The 2-year, phase III trial designated Anti-vascular endothelial growth factor (VEGF) Antibody for the Treatment of… Expand
  • table 3
  • figure 1
  • table 5
  • table 7
  • table 1
Is this relevant?
Highly Cited
2008
Highly Cited
2008
OBJECTIVE To evaluate the efficacy of photodynamic therapy (PDT) with half-dose verteporfin for treating acute central serous… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND We compared ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of… Expand
  • table 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
● PURPOSE: To determine if photodynamic therapy with verteporfin (Visudyne; Novartis AG, Bülach, Switzerland), termed verteporfin… Expand
  • table 1
  • table 2
  • table 2
  • figure 2
  • figure 1
Is this relevant?
Highly Cited
2001
Highly Cited
2001
OBJECTIVE To report 24-month vision and fluorescein angiographic outcomes from trials evaluating photodynamic therapy with… Expand
Is this relevant?
Highly Cited
1999
Highly Cited
1999
CONTEXT Risedronate, a potent bisphosphonate, has been shown to be effective in the treatment of Paget disease of bone and other… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?
Highly Cited
1999
Highly Cited
1999
  • Archives of ophthalmology
  • 1999
  • Corpus ID: 39143861
OBJECTIVE To determine if photodynamic therapy with verteporfin (Visudyne; CIBA Vision Corp, Duluth, Ga) can safely reduce the… Expand
Is this relevant?